Pacira BioSciences' Convertible Debt fell 41.56% to $280.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $280.3 million, marking a year-over-year decrease of 41.56%. This contributed to the annual value of $279.3 million for FY2024, which is 29.92% down from last year.
According to the latest figures from Q2 2025, Pacira BioSciences' Convertible Debt is $280.3 million, which was up 0.17% from $279.8 million recorded in Q1 2025.
In the past 5 years, Pacira BioSciences' Convertible Debt registered a high of $479.5 million during Q2 2024, and its lowest value of $278.9 million during Q3 2024.
Its 3-year average for Convertible Debt is $359.6 million, with a median of $397.7 million in 2023.
Per our database at Business Quant, Pacira BioSciences' Convertible Debt increased by 26.97% in 2022 and then plummeted by 41.56% in 2025.
Pacira BioSciences' Convertible Debt (Quarterly) stood at $339.3 million in 2021, then rose by 19.31% to $404.8 million in 2022, then decreased by 1.53% to $398.6 million in 2023, then declined by 29.92% to $279.3 million in 2024, then tumbled by 41.56% to $280.3 million in 2025.
Its Convertible Debt stands at $280.3 million for Q2 2025, versus $279.8 million for Q1 2025 and $279.3 million for Q4 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value